Summary
The Calcutta High Court has dismissed an appeal filed by Fraunhofer against the Patent Office's refusal of its application for a method that uses electron or X-ray irradiation to stimulate biomass growth inside a bioreactor. The Court held that the patent specification did not adequately explain how the invention actually worked, and that Fraunhofer's failure to disclose the source and geographical origin of the biological material used in the invention was, by itself, enough to defeat the application. The Court also rejected Fraunhofer's argument that the Patent Office had acted unfairly by raising new objections at the hearing stage.
Background
Fraunhofer’s patent application, filed on 26 March 2021, described a method for stimulating the growth of biomass in a liquid inside a bioreactor. The method involved exposing a portion of the liquid, up to 10%, and preferably 5%, to low-energy electrons or X-rays, and then mixing it back into the bulk volume of the bioreactor.
A request for examination was filed on 16 February 2022, and the Patent Office issued its First Examination Report on 12 July 2022. The report noted that the specification was not well structured, and lacked clarity, conciseness, and definitiveness, as required under Section 10 of the Patents Act, 1970. Fraunhofer amended its application in response, but the amendments did not satisfy the Patent Office. A hearing notice issued on 8 March 2024 raised further objections, and the application was ultimately refused by an order dated 24 May 2024, on the grounds of insufficient disclosure, lack of clarity, and non-compliance with Section 10.
Questions Before the Court
- Did the Patent Office follow the correct procedure in raising fresh objections at the hearing stage that were not part of the First Examination Report?
- Did Fraunhofer’s patent specification sufficiently describe the invention, as required under Section 10 of the Patents Act?
- Was Fraunhofer required to disclose the source and geographical origin of the biological material used in the invention, even though the biological material itself was not being claimed as the invention?
Arguments of the Parties
Fraunhofer’s Arguments
Fraunhofer argued that the Patent Office had acted unfairly by introducing fresh objections at the hearing stage that went beyond what was raised in the First Examination Report, without following the proper procedure for reopening examination. On the merits, Fraunhofer relied on the UK Supreme Court’s decision in Regeneron v Kymab to argue that patent law does not require an inventor to test every possible variation within a claimed range. It only requires the specification to teach a general principle that a person skilled in the field could use to work the invention, without needing to carry out extensive further experimentation. Fraunhofer contended that its specification met this standard, and that the Patent Office had unfairly picked out isolated phrases, such as “maximum of” and “time interval,” to make the claims appear vaguer than they actually were. Fraunhofer also argued that since the invention was a method, and did not itself claim any biological material, there was no requirement to disclose where that biological material came from.
Controller’s Arguments
The Patent Office argued that the specification was vague and incomplete in several respects. While it disclosed that a fraction of the liquid was exposed to low-energy electrons or X-rays, it did not explain the dose, duration, or cumulative effect of this exposure on the biomass. The range of acceleration voltage disclosed, 25 keV to 300 keV, was very wide, and there was no example, illustration, or data showing that the invention actually worked across this range. Terms such as “periodically,” “at most,” “a maximum of,” and time periods stretching from minutes to months made the claims too broad and indefinite to understand. The Patent Office also argued that Fraunhofer had failed to disclose the source and geographical origin of the biological material used in the invention, an omission that, in its view, was serious enough to defeat the application on its own.
Court’s Analysis
On Sufficiency of Disclosure
The Court held that a patent specification must describe the invention clearly enough for a person skilled in the field to work it, without needing to make further inventions or carry out extensive additional experimentation. Applying this standard, the Court found that Fraunhofer’s specification described a trial-and-error method over an extremely wide range of time and physical parameters, without any working example or the operating details needed to actually carry out the invention. The Court described this as a case of “shooting in the dark.” It also noted that the term “time interval” appeared only in the dependent claims, without the specification explaining what that interval should actually be, leaving the claims unclear and imprecise.
On Disclosure of Biological Material
The Court noted that Fraunhofer had itself described the biological material used in the invention as consisting of “micro-organisms, cells and/or other constituents cultivated in a bioreactor,” but had not disclosed where this material came from or its geographical origin. The Court rejected Fraunhofer’s argument that this did not matter because the biological material was not itself being claimed. It held that the law requires disclosure of the source and geographical origin of biological material whenever such material is used in an invention, regardless of whether it is separately claimed. This requirement exists to prevent biopiracy, protect India’s genetic resources, and ensure compliance with the Biological Diversity Act, 2002 and the Convention on Biological Diversity. The Court held that this omission, by itself, was serious enough to defeat the application.
On the Procedure Followed
The Court held that the objections which mattered had already been indicated in the First Examination Report, and that the hearing notice issued in March 2024 gave Fraunhofer sufficient notice of what needed to be addressed. Since Fraunhofer’s amendments did not resolve the Patent Office’s concerns, and no significant new material was added after the amendments, there was no requirement for a fresh round of examination. The Court found that Fraunhofer had the opportunity to respond to the objections and did not do so adequately, and held that there was no violation of fair procedure.
Findings
- The specification did not sufficiently describe the invention, and lacked the working examples and operating parameters needed for a person skilled in the field to carry it out.
- Fraunhofer’s failure to disclose the source and geographical origin of the biological material used in the invention was, by itself, enough to defeat the application.
- There was no violation of fair procedure in the way the Patent Office raised and addressed its objections.
- The appeal was dismissed, and the refusal of the patent application was upheld.
Relevant Paragraphs
On the specification’s lack of working examples:
“The appellant’s specification, which is based on a trial-and-error method over an infinite range of time and physical parameters has been found to be excessively broad, vague, unclear is a typical case of ‘shooting in the dark’ and hence is incapable of patentability.”
On why the source and origin of biological material must be disclosed:
“The primary object in introducing this proviso was to avoid biopiracy, maintain India’s genetic resources as its property, and also make it easier to abide by the provisions of the Biological Diversity Act, 2002, and the Convention on Biological Diversity (CBD).”
On what a patent specification is expected to give the public in return for a monopoly:
“In a patent system, monopoly by way of a patent is a privilege only in return of a complete, clear, and enabling disclosure which adds something to the public domain… The specification altogether is essentially empty. It describes functional results and gives open ranges which would necessarily lead to excessive experimentation and uncertainty.”
Citation
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschunge v. The Controller General of Patents Designs and Trade Marks and Anr., IPDPTA/11/2024, Calcutta High Court, decided 17 June 2026. Available on Indian Kanoon: http://indiankanoon.org/doc/111491224/
Disclaimer
This article is based on the author’s personal understanding of the subject. Others may hold different opinions or understandings. This article is intended for general information and does not constitute legal advice. Readers should consult an attorney before acting on any legal issue.